As Congress delays moving forward on the passage of comprehensive
health care reform, progressive state leaders from across the country
have been demanding passage of reform
as critical for families across the nation. But that doesn't mean they
are waiting; state leaders are moving forward, laying the groundwork
for how national changes should be implemented, and creating the
momentum for other meaningful health care reforms in their states.
Policy Overview: Establish a Prescriber Education Program, or “academic detailing” initiative, for the dissemination of scientific and clinical data about the effectiveness and costs of pharmaceuticals and medical devices. Such a program can reduce state health care costs and improve medical quality. States have several options for funding education programs outside of the general fund, including a fee on manufacturers and federal grants.
As part of our Shared Multi-State Agenda,
the Progressive States Network is working with legislators, advocates
and leading experts to promote Rx reforms in 2010 that will reduce
health care costs for consumers, businesses, and state and local
governments, and will help ensure access to safe and effective
medications. Through coordinated, strategic support, PSN and our
allies will be working to introduce and advance Rx reforms that will
help address state budget deficits and improve access to quality
medications in as many states possible; providing model legislation,
policy analysis, messaging and more - all of which has been gathered
and will be constantly updated on our Prescription Drug Reform Shared Agenda web page.
Policy Overview: To reap its record profits and drive up costs for families,
businesses, and government health programs, the pharmaceutical industry markets
the most expensive “celebrity” drugs over other medications that are equally or
more effective and less costly.
Whether out of circumstance or an emerging trend, where state authority
was at issue, this term the U.S. Supreme Court overwhelmingly deferred
to state decision makers-- a significant reveral from last year.
In a much anticipated decision, Wyeth v. Levine,
the Supreme Court in a 6-3 decision upheld states' right to hold the
drug industry accountable for not adequately warning consumers and
prescribers of a drug's impact. The pharmaceutical industry had argued
that Federal Drug Administration approval of a drug's warning label
pre-empts state claims of injury based on the failure by a company to
warn of additional dangers not covered by the FDA-approved label. The
court rejected this argument.